Discovery of Nanomolar DCAF1 Small Molecule Ligands.

DCAF1 is a substrate receptor of two distinct E3 ligases (CRL4DCAF1 and EDVP), plays a critical physiological role in protein degradation, and is considered a drug target for various cancers. Antagonists of DCAF1 could be used toward the development of therapeutics for cancers and viral treatments. We used the WDR domain of DCAF1 to screen a 114-billion-compound DNA encoded library (DEL) and identified candidate compounds using similarity search and machine learning. This led to the discovery of a compound (Z1391232269) with an SPR KD of 11 μM. Structure-guided hit optimization led to the discovery of OICR-8268 (26e) with an SPR KD of 38 nM and cellular target engagement with EC50 of 10 μM as measured by cellular thermal shift assay (CETSA). OICR-8268 is an excellent tool compound to enable the development of next-generation DCAF1 ligands toward cancer therapeutics, further investigation of DCAF1 functions in cells, and the development of DCAF1-based PROTACs.

[1]  S. Schreiber,et al.  Targeted Protein Degradation by Electrophilic PROTACs that Stereoselectively and Site-Specifically Engage DCAF1. , 2022, Journal of the American Chemical Society.

[2]  A. Hutchinson,et al.  Production of Recombinant PRMT Proteins using the Baculovirus Expression Vector System. , 2021, Journal of visualized experiments : JoVE.

[3]  H. Lenz,et al.  VprBP directs epigenetic gene silencing through histone H2A phosphorylation in colon cancer , 2021, Molecular oncology.

[4]  Xiaohong Zhou,et al.  HIV-1 Vpr activates host CRL4-DCAF1 E3 ligase to degrade histone deacetylase SIRT7 , 2020, Virology Journal.

[5]  B. Schulman,et al.  NEDD8 and ubiquitin ligation by cullin-RING E3 ligases. , 2020, Current opinion in structural biology.

[6]  A. Ciulli,et al.  E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones , 2020, SLAS discovery : advancing life sciences R & D.

[7]  C. Crews,et al.  PROTACs: An Emerging Therapeutic Modality in Precision Medicine. , 2020, Cell chemical biology.

[8]  Daohong Zhou,et al.  PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics , 2020, Oncogene.

[9]  Xia Tian,et al.  Machine learning on DNA-encoded libraries: A new paradigm for hit-finding , 2020, Journal of medicinal chemistry.

[10]  Danhui Ma,et al.  The PROTAC technology in drug development , 2019, Cell biochemistry and function.

[11]  P. Swanson,et al.  DCAF1 (VprBP): emerging physiological roles for a unique dual-service E3 ubiquitin ligase substrate receptor , 2018, Journal of molecular cell biology.

[12]  Kris Zimmerman,et al.  CRISPR-Mediated Tagging of Endogenous Proteins with a Luminescent Peptide. , 2017, ACS chemical biology.

[13]  N. Zheng,et al.  Ubiquitin Ligases: Structure, Function, and Regulation. , 2017, Annual review of biochemistry.

[14]  Diana Gikunju,et al.  Discovery of a Potent BTK Inhibitor with a Novel Binding Mode by Using Parallel Selections with a DNA‐Encoded Chemical Library , 2017, Chembiochem : a European journal of chemical biology.

[15]  Delowar Hossain,et al.  Cep78 controls centrosome homeostasis by inhibiting EDD‐DYRK2‐DDB1VprBP , 2017, EMBO reports.

[16]  A. Gronenborn,et al.  The DDB1–DCAF1–Vpr–UNG2 crystal structure reveals how HIV-1 Vpr steers human UNG2 toward destruction , 2016, Nature Structural &Molecular Biology.

[17]  Jeremy L. Jenkins,et al.  Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide , 2014, Nature.

[18]  Jonathan A. Cooper,et al.  Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus. , 2014, Cancer cell.

[19]  Nouri Neamati,et al.  VprBP has intrinsic kinase activity targeting histone H2A and represses gene transcription. , 2013, Molecular cell.

[20]  P. Swanson,et al.  VprBP (DCAF1): a promiscuous substrate recognition subunit that incorporates into both RING-family CRL4 and HECT-family EDD/UBR5 E3 ubiquitin ligases , 2013, BMC Molecular Biology.

[21]  H. J. Sharifi,et al.  The HIV-1 protein Vpr targets the endoribonuclease Dicer for proteasomal degradation to boost macrophage infection. , 2013, Virology.

[22]  Xiaohong Zhou,et al.  A novel DCAF1‐binding motif required for Vpx‐mediated degradation of nuclear SAMHD1 and Vpr‐induced G2 arrest , 2012, Cellular microbiology.

[23]  Matthias Rarey,et al.  A consistent description of HYdrogen bond and DEhydration energies in protein–ligand complexes: methods behind the HYDE scoring function , 2012, Journal of Computer-Aided Molecular Design.

[24]  M. Giovannini,et al.  Merlin/NF2 Functions Upstream of the Nuclear E3 Ubiquitin Ligase CRL4DCAF1 to Suppress Oncogenic Gene Expression , 2011, Science Signaling.

[25]  B. Kuhn,et al.  A Medicinal Chemist’s Guide to Molecular Interactions , 2010, Journal of medicinal chemistry.

[26]  Jonathan A. Cooper,et al.  Merlin/NF2 Suppresses Tumorigenesis by Inhibiting the E3 Ubiquitin Ligase CRL4DCAF1 in the Nucleus , 2010, Cell.

[27]  C. McCall,et al.  DDB1 functions as a linker to recruit receptor WD40 proteins to CUL4-ROC1 ubiquitin ligases. , 2006, Genes & development.

[28]  M. MacCoss,et al.  Molecular architecture and assembly of the DDB1–CUL4A ubiquitin ligase machinery , 2006, Nature.

[29]  J. Chen,et al.  A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1. , 2006, Molecular cell.

[30]  Katrin Stierand,et al.  Molecular complexes at a glance: automated generation of two-dimensional complex diagrams , 2006, Bioinform..

[31]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..